RadioBDC Logo
Lionhearted [Arty Remix] | Porter Robinson Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
MARKET MOVERS

Hospira Inc.

December 4, 2011
Text size +
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.

The maker of anesthesia and cancer treatments is being scrutinized by regulators over flaws in its manufacturing practices. It may face widespread production breakdowns that could take two to three years to correct, RBC Capital Markets analyst Shibani Malhotra said. Hospira has been working to correct flaws that led to recalls of two drugs in 2009 and 2010. It could be vulnerable to takeover, Malhotra said.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.